+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Respiratory Disease Testing Market by Test Type (Blood Tests, Imaging Tests, Pulmonary Function Tests), Component (Instruments, Reagents & Kits, Software), Age Group, Technology, Test Purpose, Diseases Type, End Users - Global Forecast 2025-2030- Product Image
Respiratory Disease Testing Market by Test Type (Blood Tests, Imaging Tests, Pulmonary Function Tests), Component (Instruments, Reagents & Kits, Software), Age Group, Technology, Test Purpose, Diseases Type, End Users - Global Forecast 2025-2030- Product Image
Sale

Respiratory Disease Testing Market by Test Type (Blood Tests, Imaging Tests, Pulmonary Function Tests), Component (Instruments, Reagents & Kits, Software), Age Group, Technology, Test Purpose, Diseases Type, End Users - Global Forecast 2025-2030

  • PDF Icon

    Report

  • 197 Pages
  • March 2025
  • Region: Global
  • 360iResearch™
  • ID: 6012368
UP TO OFF until Jan 01st 2026
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Respiratory Disease Testing Market grew from USD 6.49 billion in 2024 to USD 6.86 billion in 2025. It is expected to continue growing at a CAGR of 5.95%, reaching USD 9.18 billion by 2030.

The respiratory disease testing market is an evolving domain characterized by rapid advancements in diagnostic technologies and a heightened need for efficient clinical solutions. In recent years, the integration of innovative testing modalities with digital health solutions has transformed how diseases are identified and managed. This evolution has been largely driven by the increasing demand for early detection, accurate diagnosis, and improved patient outcomes in respiratory care. Stakeholders across healthcare systems are leveraging the latest analytical methods and data-driven insights to streamline operations, optimize resource allocation, and enhance diagnostic precision.

The market is witnessing a robust convergence of traditional clinical techniques with modern technological innovations. As the sector continues to mature, underlying factors such as population demographics, emerging health threats, and regulatory reforms have further intensified the pace of change. This dynamic environment paves the way for new entrants and established organizations alike to reassess their strategic priorities and invest in breakthrough research methodologies. In essence, the current momentum has set a clear trajectory for a transformative period in respiratory disease testing, underscoring the intertwined relationship between technology, healthcare, and patient-centric care.

Transformative Shifts in the Respiratory Disease Testing Landscape

Over the past few years, transformative shifts have redefined the respiratory disease testing landscape, challenging conventional paradigms while establishing new standards of care. Breakthroughs in diagnostic imaging and molecular technologies, coupled with the increasing integration of artificial intelligence and machine learning, have reoriented traditional testing practices. Innovative imaging techniques such as computed tomography and advanced digital radiography have improved the accuracy of pulmonary assessments, while novel immunoassays and molecular diagnostic tools are offering earlier and more precise detection capabilities.

These technological strides are complemented by a global drive towards personalized medicine, where diagnostics are tailored according to individual patient profiles. As regulatory bodies update standards to keep pace with scientific advancements, there has also been a surge in investments in research and development by both public and private sectors. The confluence of these factors has accelerated market growth, making the industry more agile and responsive to emerging respiratory health challenges. Additionally, a renewed focus on reducing diagnosis turnaround times and enhancing data transparency further bolsters the transition towards a more efficient and patient-focused testing framework.

Key Insights on Segmentation in Respiratory Disease Testing

A detailed segmentation analysis reveals a multifaceted market structure that caters to diverse diagnostic needs and patient demographics. The market is examined based on test type, where analysis spans blood tests, imaging tests, and pulmonary function tests with imaging tests further dissected into chest X-ray and computed tomography examinations. Components of the testing process are equally critical, requiring insights into instruments, reagents and kits, and specialized software that drives efficient diagnostics. The segmentation extends to age groups, addressing specific needs for adults, geriatrics, and pediatrics, ensuring that diagnostic approaches are tailored for every life stage.

Technological segmentation offers an intricate view of the diverse methodologies in the market, integrating imaging technologies, immunoassays, microbiology, and molecular diagnostics. In addition, the purpose of testing is segmented to focus on diagnosis, monitoring, prognosis, and screening, each catering to unique clinical requirements. Disease types are also a significant focus, with analysis covering conditions such as asthma, chronic obstructive pulmonary disease where chronic bronchitis and emphysema are specifically examined, infectious respiratory diseases including influenza, pneumonia, and tuberculosis, as well as lung cancer. Finally, segmentation by end users encompasses diagnostic laboratories, home care settings, hospitals and clinics, and research laboratories, each playing a pivotal role in the effective delivery of respiratory health services. This granular segmentation provides clarity on market dynamics and informs the strategic direction for future innovations.

Based on Test Type, market is studied across Blood Tests, Imaging Tests, and Pulmonary Function Tests. The Imaging Tests is further studied across Chest X-Ray and Computed Tomography.

Based on Component, market is studied across Instruments, Reagents & Kits, and Software.

Based on Age Group, market is studied across Adults, Geriatrics, and Pediatrics.

Based on Technology, market is studied across Imaging Technologies, Immunoassays, Microbiology, and Molecular Diagnostics.

Based on Test Purpose, market is studied across Diagnosis, Monitoring, Prognosis, and Screening.

Based on Diseases Type, market is studied across Asthma, Chronic Obstructive Pulmonary Disease (COPD), Infectious Respiratory Diseases, and Lung Cancer. The Chronic Obstructive Pulmonary Disease (COPD) is further studied across Chronic Bronchitis and Emphysema. The Infectious Respiratory Diseases is further studied across Influenza, Pneumonia, and Tuberculosis.

Based on End Users, market is studied across Diagnostic Laboratories, Home Care Settings, Hospitals & Clinics, and Research Laboratories.

Regional Trends Shaping the Market

Regional insights elucidate the nuances of market behavior across key geographies. In the Americas, technological innovations are coupled with strong regulatory frameworks and significant investments in public health infrastructure, driving robust market growth. Similarly, the Europe, Middle East & Africa region is characterized by a blend of established health systems and emerging markets where government initiatives and private sector partnerships are catalyzing rapid adoption of advanced testing methodologies. The interplay of socio-economic factors and healthcare investments here creates a fertile ground for sustainable growth and innovation.

In the Asia-Pacific region, increasing healthcare awareness coupled with rising incidences of respiratory ailments has spurred substantial market activity. Economic expansion and urbanization, along with improvements in healthcare infrastructure, are propelling demand for state-of-the-art respiratory disease testing. The balance between cost-effective solutions and technological sophistication remains a guiding factor in market adoption across these regions. These regional insights offer a comprehensive overview of the diverse factors influencing market dynamics and underscore the importance of strategic regional investments and policy adaptations.

Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

Competitive Landscape and Company Insights

The competitive landscape within the respiratory disease testing market is defined by a blend of global conglomerates and innovative startups, each contributing unique technological competencies to the evolving sector. Industry leaders such as Abbott Laboratories, AstraZeneca PLC, and Becton, Dickinson and Company have long been recognized for their contributions to healthcare innovation. In parallel, Bio-Rad Laboratories, Inc., Biomérieux PLC, and Charles River Laboratories continue to push the boundaries of diagnostic excellence. Additionally, companies like COSMED srl, Eurofins Viracor, LLC, and F. Hoffmann-La Roche Ltd. have cemented their positions through sustained investments in advanced diagnostic technologies.

Further reinforcing the competitive environment, prominent players such as Fujifilm Holdings, GE Healthcare, and Koninklijke Philips N.V have been pivotal in integrating cutting‐edge imaging solutions with diagnostic testing. The market also sees significant contributions from Medtronic PLC, MGC Diagnostics Corporation by Caire Inc., QIAGEN Group, ResMed, and SDI Diagnostics, Inc., whose strategies increasingly focus on precision diagnostics and data integration. Meanwhile, organizations including Seegene Inc., Siemens Healthineers AG, and Thermo Fisher Scientific maintain strong global footprints through innovative product offerings and strategic market positioning. This diverse yet consolidated competitive landscape is a testament to the market’s rapid evolution and its capacity for continual innovation.

The report delves into recent significant developments in the Respiratory Disease Testing Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, AstraZeneca PLC, Becton, Dickinson and Company, Bio-Rad Laboratories, Inc., Biomérieux PLC, Charles River Laboratories, COSMED srl, Eurofins Viracor, LLC, F. Hoffmann-La Roche Ltd., Fujifilm Holdings, GE Healthcare, Koninklijke Philips N.V, Medtronic PLC, MGC Diagnostics Corporation by Caire Inc., QIAGEN Group, ResMed, SDI Diagnostics, Inc., Seegene Inc., Seimens Healthineers AG, and Thermo Fisher Scientific.

Actionable Strategies for Industry Leaders

For industry leaders aiming to navigate the complex landscape of respiratory disease testing, several strategic imperatives emerge. Embracing technological advancements is crucial; organizations should invest in scalable diagnostic platforms that integrate modern imaging solutions, molecular diagnostics, and real-time data analytics. It is essential to foster partnerships with academic institutions, industry experts, and technology providers to co-develop next-generation diagnostic tools that can address both current and emerging respiratory challenges.

Organizations must also prioritize agility by aligning their operational strategies with evolving regulatory standards and patient-centric care models. Leveraging data-driven insights can streamline product development processes, optimize supply chains, and enhance customer engagement efforts. Focused investments in research and innovation, alongside a commitment to training and retaining skilled professionals, will ensure that companies remain competitive. Moreover, diversification of product portfolios to include comprehensive testing solutions that cater to varied segments - from test types and technological approaches to age-specific and disease-specific needs - is paramount. These strategic actions will not only enhance market presence but also contribute significantly to improved patient outcomes and operational efficiencies across the sector.

In summing up the current executive overview, the respiratory disease testing market emerges as a dynamic and rapidly evolving field characterized by transformational technological shifts and evolving segmentation strategies. The analysis reflects a market that is not only responsive to clinical imperatives but also driven by innovations in imaging, molecular diagnostics, and integrative software solutions. A detailed segmentation approach has revealed the multifaceted nature of the market, addressing diverse needs from test types and technological advancements to age-specific applications and disease-specific investigations.

Regional trends emphasize the importance of targeted strategies that reflect the unique characteristics of each geography, while insights into competitive dynamics highlight a landscape where established industry leaders continue to pave the way for emerging technologies. Overall, these insights underline the importance of strategic agility and the need for continuous investment in research and development. By acknowledging these factors, stakeholders can better position themselves to not only meet current challenges but also to harness future opportunities within the respiratory disease testing market.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Expanding awareness and increasing prevalence of respiratory illnesses necessitate advanced testing
5.1.1.2. Government initiatives and funding are bolstering research and development of respiratory diagnostics
5.1.1.3. Rise in pollution levels worldwide contributing to increased respiratory ailments and testing demand
5.1.2. Restraints
5.1.2.1. High costs associated with the development and implementation of new diagnostic technologies
5.1.3. Opportunities
5.1.3.1. Integration of artificial intelligence and data analytics in improving diagnostic test accuracy and speed
5.1.3.2. Surge in demand for personalized healthcare solutions stimulates advancements in respiratory testing
5.1.4. Challenges
5.1.4.1. Regulatory and compliance challenges associated with respiratory disease testing solutions
5.2. Market Segmentation Analysis
5.2.1. Component: Rising prevalence of respiratory ailments accelerates the need for reagents & kits
5.2.2. End Users: Growing importance of diagnostic laboratories as they facilitate high-throughput and detailed analysis
5.3. Porter’s Five Forces Analysis
5.3.1. Threat of New Entrants
5.3.2. Threat of Substitutes
5.3.3. Bargaining Power of Customers
5.3.4. Bargaining Power of Suppliers
5.3.5. Industry Rivalry
5.4. PESTLE Analysis
5.4.1. Political
5.4.2. Economic
5.4.3. Social
5.4.4. Technological
5.4.5. Legal
5.4.6. Environmental
6. Respiratory Disease Testing Market, by Test Type
6.1. Introduction
6.2. Blood Tests
6.3. Imaging Tests
6.3.1. Chest X-Ray
6.3.2. Computed Tomography
6.4. Pulmonary Function Tests
7. Respiratory Disease Testing Market, by Component
7.1. Introduction
7.2. Instruments
7.3. Reagents & Kits
7.4. Software
8. Respiratory Disease Testing Market, by Age Group
8.1. Introduction
8.2. Adults
8.3. Geriatrics
8.4. Pediatrics
9. Respiratory Disease Testing Market, by Technology
9.1. Introduction
9.2. Imaging Technologies
9.3. Immunoassays
9.4. Microbiology
9.5. Molecular Diagnostics
10. Respiratory Disease Testing Market, by Test Purpose
10.1. Introduction
10.2. Diagnosis
10.3. Monitoring
10.4. Prognosis
10.5. Screening
11. Respiratory Disease Testing Market, by Diseases Type
11.1. Introduction
11.2. Asthma
11.3. Chronic Obstructive Pulmonary Disease (COPD)
11.3.1. Chronic Bronchitis
11.3.2. Emphysema
11.4. Infectious Respiratory Diseases
11.4.1. Influenza
11.4.2. Pneumonia
11.4.3. Tuberculosis
11.5. Lung Cancer
12. Respiratory Disease Testing Market, by End Users
12.1. Introduction
12.2. Diagnostic Laboratories
12.3. Home Care Settings
12.4. Hospitals & Clinics
12.5. Research Laboratories
13. Americas Respiratory Disease Testing Market
13.1. Introduction
13.2. Argentina
13.3. Brazil
13.4. Canada
13.5. Mexico
13.6. United States
14. Asia-Pacific Respiratory Disease Testing Market
14.1. Introduction
14.2. Australia
14.3. China
14.4. India
14.5. Indonesia
14.6. Japan
14.7. Malaysia
14.8. Philippines
14.9. Singapore
14.10. South Korea
14.11. Taiwan
14.12. Thailand
14.13. Vietnam
15. Europe, Middle East & Africa Respiratory Disease Testing Market
15.1. Introduction
15.2. Denmark
15.3. Egypt
15.4. Finland
15.5. France
15.6. Germany
15.7. Israel
15.8. Italy
15.9. Netherlands
15.10. Nigeria
15.11. Norway
15.12. Poland
15.13. Qatar
15.14. Russia
15.15. Saudi Arabia
15.16. South Africa
15.17. Spain
15.18. Sweden
15.19. Switzerland
15.20. Turkey
15.21. United Arab Emirates
15.22. United Kingdom
16. Competitive Landscape
16.1. Market Share Analysis, 2024
16.2. FPNV Positioning Matrix, 2024
16.3. Competitive Scenario Analysis
16.3.1. Roche enhances respiratory disease diagnostics with advanced multi-virus detection test technology
16.3.2. NIH-backed study has developed an experimental blood test to predict severe respiratory diseases
16.3.3. New national centre launched to improve tests and treatments for respiratory diseases
16.4. Strategy Analysis & Recommendation
List of Figures
FIGURE 1. RESPIRATORY DISEASE TESTING MARKET MULTI-CURRENCY
FIGURE 2. RESPIRATORY DISEASE TESTING MARKET MULTI-LANGUAGE
FIGURE 3. RESPIRATORY DISEASE TESTING MARKET RESEARCH PROCESS
FIGURE 4. RESPIRATORY DISEASE TESTING MARKET SIZE, 2024 VS 2030
FIGURE 5. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 6. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 8. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY TEST TYPE, 2024 VS 2030 (%)
FIGURE 9. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY TEST TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 10. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY COMPONENT, 2024 VS 2030 (%)
FIGURE 11. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY COMPONENT, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 12. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY AGE GROUP, 2024 VS 2030 (%)
FIGURE 13. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY AGE GROUP, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 14. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY TECHNOLOGY, 2024 VS 2030 (%)
FIGURE 15. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY TECHNOLOGY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 16. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY TEST PURPOSE, 2024 VS 2030 (%)
FIGURE 17. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY TEST PURPOSE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 18. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY DISEASES TYPE, 2024 VS 2030 (%)
FIGURE 19. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY DISEASES TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 20. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY END USERS, 2024 VS 2030 (%)
FIGURE 21. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY END USERS, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 22. AMERICAS RESPIRATORY DISEASE TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 23. AMERICAS RESPIRATORY DISEASE TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 24. UNITED STATES RESPIRATORY DISEASE TESTING MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 25. UNITED STATES RESPIRATORY DISEASE TESTING MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 26. ASIA-PACIFIC RESPIRATORY DISEASE TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 27. ASIA-PACIFIC RESPIRATORY DISEASE TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 28. EUROPE, MIDDLE EAST & AFRICA RESPIRATORY DISEASE TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 29. EUROPE, MIDDLE EAST & AFRICA RESPIRATORY DISEASE TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 30. RESPIRATORY DISEASE TESTING MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 31. RESPIRATORY DISEASE TESTING MARKET, FPNV POSITIONING MATRIX, 2024
List of Tables
TABLE 1. RESPIRATORY DISEASE TESTING MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. RESPIRATORY DISEASE TESTING MARKET DYNAMICS
TABLE 7. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY BLOOD TESTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY IMAGING TESTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY CHEST X-RAY, BY REGION, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY COMPUTED TOMOGRAPHY, BY REGION, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY PULMONARY FUNCTION TESTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY INSTRUMENTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY REAGENTS & KITS, BY REGION, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY SOFTWARE, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY ADULTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY GERIATRICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY PEDIATRICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY IMAGING TECHNOLOGIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY IMMUNOASSAYS, BY REGION, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY MICROBIOLOGY, BY REGION, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY TEST PURPOSE, 2018-2030 (USD MILLION)
TABLE 28. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY DIAGNOSIS, BY REGION, 2018-2030 (USD MILLION)
TABLE 29. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY MONITORING, BY REGION, 2018-2030 (USD MILLION)
TABLE 30. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY PROGNOSIS, BY REGION, 2018-2030 (USD MILLION)
TABLE 31. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY SCREENING, BY REGION, 2018-2030 (USD MILLION)
TABLE 32. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY DISEASES TYPE, 2018-2030 (USD MILLION)
TABLE 33. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY ASTHMA, BY REGION, 2018-2030 (USD MILLION)
TABLE 34. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD), BY REGION, 2018-2030 (USD MILLION)
TABLE 35. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY CHRONIC BRONCHITIS, BY REGION, 2018-2030 (USD MILLION)
TABLE 36. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY EMPHYSEMA, BY REGION, 2018-2030 (USD MILLION)
TABLE 37. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD), 2018-2030 (USD MILLION)
TABLE 38. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY INFECTIOUS RESPIRATORY DISEASES, BY REGION, 2018-2030 (USD MILLION)
TABLE 39. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY INFLUENZA, BY REGION, 2018-2030 (USD MILLION)
TABLE 40. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY PNEUMONIA, BY REGION, 2018-2030 (USD MILLION)
TABLE 41. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY TUBERCULOSIS, BY REGION, 2018-2030 (USD MILLION)
TABLE 42. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY INFECTIOUS RESPIRATORY DISEASES, 2018-2030 (USD MILLION)
TABLE 43. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY LUNG CANCER, BY REGION, 2018-2030 (USD MILLION)
TABLE 44. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
TABLE 45. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 46. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY HOME CARE SETTINGS, BY REGION, 2018-2030 (USD MILLION)
TABLE 47. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 48. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY RESEARCH LABORATORIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 49. AMERICAS RESPIRATORY DISEASE TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 50. AMERICAS RESPIRATORY DISEASE TESTING MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
TABLE 51. AMERICAS RESPIRATORY DISEASE TESTING MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
TABLE 52. AMERICAS RESPIRATORY DISEASE TESTING MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 53. AMERICAS RESPIRATORY DISEASE TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 54. AMERICAS RESPIRATORY DISEASE TESTING MARKET SIZE, BY TEST PURPOSE, 2018-2030 (USD MILLION)
TABLE 55. AMERICAS RESPIRATORY DISEASE TESTING MARKET SIZE, BY DISEASES TYPE, 2018-2030 (USD MILLION)
TABLE 56. AMERICAS RESPIRATORY DISEASE TESTING MARKET SIZE, BY CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD), 2018-2030 (USD MILLION)
TABLE 57. AMERICAS RESPIRATORY DISEASE TESTING MARKET SIZE, BY INFECTIOUS RESPIRATORY DISEASES, 2018-2030 (USD MILLION)
TABLE 58. AMERICAS RESPIRATORY DISEASE TESTING MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
TABLE 59. AMERICAS RESPIRATORY DISEASE TESTING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 60. ARGENTINA RESPIRATORY DISEASE TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 61. ARGENTINA RESPIRATORY DISEASE TESTING MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
TABLE 62. ARGENTINA RESPIRATORY DISEASE TESTING MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
TABLE 63. ARGENTINA RESPIRATORY DISEASE TESTING MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 64. ARGENTINA RESPIRATORY DISEASE TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 65. ARGENTINA RESPIRATORY DISEASE TESTING MARKET SIZE, BY TEST PURPOSE, 2018-2030 (USD MILLION)
TABLE 66. ARGENTINA RESPIRATORY DISEASE TESTING MARKET SIZE, BY DISEASES TYPE, 2018-2030 (USD MILLION)
TABLE 67. ARGENTINA RESPIRATORY DISEASE TESTING MARKET SIZE, BY CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD), 2018-2030 (USD MILLION)
TABLE 68. ARGENTINA RESPIRATORY DISEASE TESTING MARKET SIZE, BY INFECTIOUS RESPIRATORY DISEASES, 2018-2030 (USD MILLION)
TABLE 69. ARGENTINA RESPIRATORY DISEASE TESTING MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
TABLE 70. BRAZIL RESPIRATORY DISEASE TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 71. BRAZIL RESPIRATORY DISEASE TESTING MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
TABLE 72. BRAZIL RESPIRATORY DISEASE TESTING MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
TABLE 73. BRAZIL RESPIRATORY DISEASE TESTING MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 74. BRAZIL RESPIRATORY DISEASE TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 75. BRAZIL RESPIRATORY DISEASE TESTING MARKET SIZE, BY TEST PURPOSE, 2018-2030 (USD MILLION)
TABLE 76. BRAZIL RESPIRATORY DISEASE TESTING MARKET SIZE, BY DISEASES TYPE, 2018-2030 (USD MILLION)
TABLE 77. BRAZIL RESPIRATORY DISEASE TESTING MARKET SIZE, BY CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD), 2018-2030 (USD MILLION)
TABLE 78. BRAZIL RESPIRATORY DISEASE TESTING MARKET SIZE, BY INFECTIOUS RESPIRATORY DISEASES, 2018-2030 (USD MILLION)
TABLE 79. BRAZIL RESPIRATORY DISEASE TESTING MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
TABLE 80. CANADA RESPIRATORY DISEASE TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 81. CANADA RESPIRATORY DISEASE TESTING MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
TABLE 82. CANADA RESPIRATORY DISEASE TESTING MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
TABLE 83. CANADA RESPIRATORY DISEASE TESTING MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 84. CANADA RESPIRATORY DISEASE TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 85. CANADA RESPIRATORY DISEASE TESTING MARKET SIZE, BY TEST PURPOSE, 2018-2030 (USD MILLION)
TABLE 86. CANADA RESPIRATORY DISEASE TESTING MARKET SIZE, BY DISEASES TYPE, 2018-2030 (USD MILLION)
TABLE 87. CANADA RESPIRATORY DISEASE TESTING MARKET SIZE, BY CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD), 2018-2030 (USD MILLION)
TABLE 88. CANADA RESPIRATORY DISEASE TESTING MARKET SIZE, BY INFECTIOUS RESPIRATORY DISEASES, 2018-2030 (USD MILLION)
TABLE 89. CANADA RESPIRATORY DISEASE TESTING MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
TABLE 90. MEXICO RESPIRATORY DISEASE TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 91. MEXICO RESPIRATORY DISEASE TESTING MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
TABLE 92. MEXICO RESPIRATORY DISEASE TESTING MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
TABLE 93. MEXICO RESPIRATORY DISEASE TESTING MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 94. MEXICO RESPIRATORY DISEASE TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 95. MEXICO RESPIRATORY DISEASE TESTING MARKET SIZE, BY TEST PURPOSE, 2018-2030 (USD MILLION)
TABLE 96. MEXICO RESPIRATORY DISEASE TESTING MARKET SIZE, BY DISEASES TYPE, 2018-2030 (USD MILLION)
TABLE 97. MEXICO RESPIRATORY DISEASE TESTING MARKET SIZE, BY CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD), 2018-2030 (USD MILLION)
TABLE 98. MEXICO RESPIRATORY DISEASE TESTING MARKET SIZE, BY INFECTIOUS RESPIRATORY DISEASES, 2018-2030 (USD MILLION)
TABLE 99. MEXICO RESPIRATORY DISEASE TESTING MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
TABLE 100. UNITED STATES RESPIRATORY DISEASE TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 101. UNITED STATES RESPIRATORY DISEASE TESTING MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
TABLE 102. UNITED STATES RESPIRATORY DISEASE TESTING MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
TABLE 103. UNITED STATES RESPIRATORY DISEASE TESTING MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 104. UNITED STATES RESPIRATORY DISEASE TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 105. UNITED STATES RESPIRATORY DISEASE TESTING MARKET SIZE, BY TEST PURPOSE, 2018-2030 (USD MILLION)
TABLE 106. UNITED STATES RESPIRATORY DISEASE TESTING MARKET SIZE, BY DISEASES TYPE, 2018-2030 (USD MILLION)
TABLE 107. UNITED STATES RESPIRATORY DISEASE TESTING MARKET SIZE, BY CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD), 2018-2030 (USD MILLION)
TABLE 108. UNITED STATES RESPIRATORY DISEASE TESTING MARKET SIZE, BY INFECTIOUS RESPIRATORY DISEASES, 2018-2030 (USD MILLION)
TABLE 109. UNITED STATES RESPIRATORY DISEASE TESTING MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
TABLE 110. UNITED STATES RESPIRATORY DISEASE TESTING MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 111. ASIA-PACIFIC RESPIRATORY DISEASE TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 112. ASIA-PACIFIC RESPIRATORY DISEASE TESTING MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
TABLE 113. ASIA-PACIFIC RESPIRATORY DISEASE TESTING MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
TABLE 114. ASIA-PACIFIC RESPIRATORY DISEASE TESTING MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 115. ASIA-PACIFIC RESPIRATORY DISEASE TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 116. ASIA-PACIFIC RESPIRATORY DISEASE TESTING MARKET SIZE, BY TEST PURPOSE, 2018-2030 (USD MILLION)
TABLE 117. ASIA-PACIFIC RESPIRATORY DISEASE TESTING MARKET SIZE, BY DISEASES TYPE, 2018-2030 (USD MILLION)
TABLE 118. ASIA-PACIFIC RESPIRATORY DISEASE TESTING MARKET SIZE, BY CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD), 2018-2030 (USD MILLION)
TABLE 119. ASIA-PACIFIC RESPIRATORY DISEASE TESTING MARKET SIZE, BY INFECTIOUS RESPIRATORY DISEASES, 2018-2030 (USD MILLION)
TABLE 120. ASIA-PACIFIC RESPIRATORY DISEASE TESTING MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
TABLE 121. ASIA-PACIFIC RESPIRATORY DISEASE TESTING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 122. AUSTRALIA RESPIRATORY DISEASE TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 123. AUSTRALIA RESPIRATORY DISEASE TESTING MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
TABLE 124. AUSTRALIA RESPIRATORY DISEASE TESTING MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
TABLE 125. AUSTRALIA RESPIRATORY DISEASE TESTING MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 126. AUSTRALIA RESPIRATORY DISEASE TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 127. AUSTRALIA RESPIRATORY DISEASE TESTING MARKET SIZE, BY TEST PURPOSE, 2018-2030 (USD MILLION)
TABLE 128. AUSTRALIA RESPIRATORY DISEASE TESTING MARKET SIZE, BY DISEASES TYPE, 2018-2030 (USD MILLION)
TABLE 129. AUSTRALIA RESPIRATORY DISEASE TESTING MARKET SIZE, BY CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD), 2018-2030 (USD MILLION)
TABLE 130. AUSTRALIA RESPIRATORY DISEASE TESTING MARKET SIZE, BY INFECTIOUS RESPIRATORY DISEASES, 2018-2030 (USD MILLION)
TABLE 131. AUSTRALIA RESPIRATORY DISEASE TESTING MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
TABLE 132. CHINA RESPIRATORY DISEASE TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 133. CHINA RESPIRATORY DISEASE TESTING MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
TABLE 134. CHINA RESPIRATORY DISEASE TESTING MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
TABLE 135. CHINA RESPIRATORY DISEASE TESTING MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 136. CHINA RESPIRATORY DISEASE TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 137. CHINA RESPIRATORY DISEASE TESTING MARKET SIZE, BY TEST PURPOSE, 2018-2030 (USD MILLION)
TABLE 138. CHINA RESPIRATORY DISEASE TESTING MARKET SIZE, BY DISEASES TYPE, 2018-2030 (USD MILLION)
TABLE 139. CHINA RESPIRATORY DISEASE TESTING MARKET SIZE, BY CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD), 2018-2030 (USD MILLION)
TABLE 140. CHINA RESPIRATORY DISEASE TESTING MARKET SIZE, BY INFECTIOUS RESPIRATORY DISEASES, 2018-2030 (USD MILLION)
TABLE 141. CHINA RESPIRATORY DISEASE TESTING MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
TABLE 142. INDIA RESPIRATORY DISEASE TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 143. INDIA RESPIRATORY DISEASE TESTING MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
TABLE 144. INDIA RESPIRATORY DISEASE TESTING MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
TABLE 145. INDIA RESPIRATORY DISEASE TESTING MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 146. INDIA RESPIRATORY DISEASE TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 147. INDIA RESPIRATORY DISEASE TESTING MARKET SIZE, BY TEST PURPOSE, 2018-2030 (USD MILLION)
TABLE 148. INDIA RESPIRATORY DISEASE TESTING MARKET SIZE, BY DISEASES TYPE, 2018-2030 (USD MILLION)
TABLE 149. INDIA RESPIRATORY DISEASE TESTING MARKET SIZE, BY CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD), 2018-2030 (USD MILLION)
TABLE 150. INDIA RESPIRATORY DISEASE TESTING MARKET SIZE, BY INFECTIOUS RESPIRATORY DISEASES, 2018-2030 (USD MILLION)
TABLE 151. INDIA RESPIRATORY DISEASE TESTING MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
TABLE 152. INDONESIA RESPIRATORY DISEASE TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 153. INDONESIA RESPIRATORY DISEASE TESTING MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
TABLE 154. INDONESIA RESPIRATORY DISEASE TESTING MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
TABLE 155. INDONESIA RESPIRATORY DISEASE TESTING MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 156. INDONESIA RESPIRATORY DISEASE TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 157. INDONESIA RESPIRATORY DISEASE TESTING MARKET SIZE, BY TEST PURPOSE, 2018-2030 (USD MILLION)
TABLE 158. INDONESIA RESPIRATORY DISEASE TESTING MARKET SIZE, BY DISEASES TYPE, 2018-2030 (USD MILLION)
TABLE 159. INDONESIA RESPIRATORY DISEASE TESTING MARKET SIZE, BY CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD), 2018-2030 (USD MILLION)
TABLE 160. INDONESIA RESPIRATORY DISEASE TESTING MARKET SIZE, BY INFECTIOUS RESPIRATORY DISEASES, 2018-2030 (USD MILLION)
TABLE 161. INDONESIA RESPIRATORY DISEASE TESTING MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
TABLE 162. JAPAN RESPIRATORY DISEASE TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 163. JAPAN RESPIRATORY DISEASE TESTING MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
TABLE 164. JAPAN RESPIRATORY DISEASE TESTING MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
TABLE 165. JAPAN RESPIRATORY DISEASE TESTING MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 166. JAPAN RESPIRATORY DISEASE TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 167. JAPAN RESPIRATORY DISEASE TESTING MARKET SIZE, BY TEST PURPOSE, 2018-2030 (USD MILLION)
TABLE 168. JAPAN RESPIRATORY DISEASE TESTING MARKET SIZE, BY DISEASES TYPE, 2018-2030 (USD MILLION)
TABLE 169. JAPAN RESPIRATORY DISEASE TESTING MARKET SIZE, BY CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD), 2018-2030 (USD MILLION)
TABLE 170. JAPAN RESPIRATORY DISEASE TESTING MARKET SIZE, BY INFECTIOUS RESPIRATORY DISEASES, 2018-2030 (USD MILLION)
TABLE 171. JAPAN RESPIRATORY DISEASE TESTING MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
TABLE 172. MALAYSIA RESPIRATORY DISEASE TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 173. MALAYSIA RESPIRATORY DISEASE TESTING MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
TABLE 174. MALAYSIA RESPIRATORY DISEASE TESTING MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
TABLE 175. MALAYSIA RESPIRATORY DISEASE TESTING MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 176. MALAYSIA RESPIRATORY DISEASE TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 177. MALAYSIA RESPIRATORY DISEASE TESTING MARKET SIZE, BY TEST PURPOSE, 2018-2030 (USD MILLION)
TABLE 178. MALAYSIA RESPIRATORY DISEASE TESTING MARKET SIZE, BY DISEASES TYPE, 2018-2030 (USD MILLION)
TABLE 179. MALAYSIA RESPIRATORY DISEASE TESTING MARKET SIZE, BY CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD), 2018-2030 (USD MILLION)
TABLE 180. MALAYSIA RESPIRATORY DISEASE TESTING MARKET SIZE, BY INFECTIOUS RESPIRATORY DISEASES, 2018-2030 (USD MILLION)
TABLE 181. MALAYSIA RESPIRATORY DISEASE TESTING MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
TABLE 182. PHILIPPINES RESPIRATORY DISEASE TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 183. PHILIPPINES RESPIRATORY DISEASE TESTING MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
TABLE 184. PHILIPPINES RESPIRATORY DISEASE TESTING MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
TABLE 185. PHILIPPINES RESPIRATORY DISEASE TESTING MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 186. PHILIPPINES RESPIRATORY DISEASE TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 187. PHILIPPINES RESPIRATORY DISEASE TESTING MARKET SIZE, BY TEST PURPOSE, 2018-2030 (USD MILLION)
TABLE 188. PHILIPPINES RESPIRATORY DISEASE TESTING MARKET SIZE, BY DISEASES TYPE, 2018-2030 (USD MILLION)
TABLE 189. PHILIPPINES RESPIRATORY DISEASE TESTING MARKET SIZE, BY CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD), 2018-2030 (USD MILLION)
TABLE 190. PHILIPPINES RESPIRATORY DISEASE TESTING MARKET SIZE, BY INFECTIOUS RESPIRATORY DISEASES, 2018-2030 (USD MILLION)
TABLE 191. PHILIPPINES RESPIRATORY DISEASE TESTING MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
TABLE 192. SINGAPORE RESPIRATORY DISEASE TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 193. SINGAPORE RESPIRATORY DISEASE TESTING MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
TABLE 194. SINGAPORE RESPIRATORY DISEASE TESTING MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
TABLE 195. SINGAPORE RESPIRATORY DISEASE TESTING MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 196. SINGAPORE RESPIRATORY DISEASE TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 197. SINGAPORE RESPIRATORY DISEASE TESTING MARKET SIZE, BY TEST PURPOSE, 2018-2030 (USD MILLION)
TABLE 198. SINGAPORE RESPIRATORY DISEASE TESTING MARKET SIZE, BY DISEASES TYPE, 2018-2030 (USD MILLION)
TABLE 199. SINGAPORE RESPIRATORY DISEASE TESTING MARKET SIZE, BY CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD), 2018-2030 (USD MILLION)
TABLE 200. SINGAPORE RESPIRATORY DISEASE TESTING MARKET SIZE, BY INFECTIOUS RESPIRATORY DISEASES, 2018-2030 (USD MILLION)
TABLE 201. SINGAPORE RESPIRATORY DISEASE TESTING MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
TABLE 202. SOUTH KOREA RESPIRATORY DISEASE TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 203. SOUTH KOREA RESPIRATORY DISEASE TESTING MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
TABLE 204. SOUTH KOREA RESPIRATORY DISEASE TESTING MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
TABLE 205. SOUTH KOREA RESPIRATORY DISEASE TESTING MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 206. SOUTH KOREA RESPIRATORY DISEASE TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 207. SOUTH KOREA RESPIRATORY DISEASE TESTING MARKET SIZE, BY TEST PURPOSE, 2018-2030 (USD MILLION)
TABLE 208. SOUTH KOREA RESPIRATORY DISEASE TESTING MARKET SIZE, BY DISEASES TYPE, 2018-2030 (USD MILLION)
TABLE 209. SOUTH KOREA RESPIRATORY DISEASE TESTING MARKET SIZE, BY CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD), 2018-2030 (USD MILLION)
TABLE 210. SOUTH KOREA RESPIRATORY DISEASE TESTING MARKET SIZE, BY INFECTIOUS RESPIRATORY DISEASES, 2018-2030 (USD MILLION)
TABLE 211. SOUTH KOREA RESPIRATORY DISEASE TESTING MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
TABLE 212. TAIWAN RESPIRATORY DISEASE TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 213. TAIWAN RESPIRATORY DISEASE TESTING MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
TABLE 214. TAIWAN RESPIRATORY DISEASE TESTING MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
TABLE 215. TAIWAN RESPIRATORY DISEASE TESTING MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 216. TAIWAN RESPIRATORY DISEASE TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 217. TAIWAN RESPIRATORY DISEASE TESTING MARKET SIZE, BY TEST PURPOSE, 2018-2030 (USD MILLION)
TABLE 218. TAIWAN RESPIRATORY DISEASE TESTING MARKET SIZE, BY DISEASES TYPE, 2018-2030 (USD MILLION)
TABLE 219. TAIWAN RESPIRATORY DISEASE TESTING MARKET SIZE, BY CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD), 2018-2030 (USD MILLION)
TABLE 220. TAIWAN RESPIRATORY DISEASE TESTING MARKET SIZE, BY INFECTIOUS RESPIRATORY DISEASES, 2018-2030 (USD MILLION)
TABLE 221. TAIWAN RESPIRATORY DISEASE TESTING MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
TABLE 222. THAILAND RESPIRATORY DISEASE TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 223. THAILAND RESPIRATORY DISEASE TESTING MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
TABLE 224. THAILAND RESPIRATORY DISEASE TESTING MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
TABLE 225. THAILAND RESPIRATORY DISEASE TESTING MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 226. THAILAND RESPIRATORY DISEASE TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 227. THAILAND RESPIRATORY DISEASE TESTING MARKET SIZE, BY TEST PURPOSE, 2018-2030 (USD MILLION)
TABLE 228. THAILAND RESPIRATORY DISEASE TESTING MARKET SIZE, BY DISEASES TYPE, 2018-2030 (USD MILLION)
TABLE 229. THAILAND RESPIRATORY DISEASE TESTING MARKET SIZE, BY CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD), 2018-2030 (USD MILLION)
TABLE 230. THAILAND RESPIRATORY DISEASE TESTING MARKET SIZE, BY INFECTIOUS RESPIRATORY DISEASES, 2018-2030 (USD MILLION)
TABLE 231. THAILAND RESPIRATORY DISEASE TESTING MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
TABLE 232. VIETNAM RESPIRATORY DISEASE TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 233. VIETNAM RESPIRATORY DISEASE TESTING MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
TABLE 234. VIETNAM RESPIRATORY DISEASE TESTING MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
TABLE 235. VIETNAM RESPIRATORY DISEASE TESTING MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 236. VIETNAM RESPIRATORY DISEASE TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 237. VIETNAM RESPIRATORY DISEASE TESTING MARKET SIZE, BY TEST PURPOSE, 2018-2030 (USD MILLION)
TABLE 238. VIETNAM RESPIRATORY DISEASE TESTING MARKET SIZE, BY DISEASES TYPE, 2018-2030 (USD MILLION)
TABLE 239. VIETNAM RESPIRATORY DISEASE TESTING MARKET SIZE, BY CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD), 2018-2030 (USD MILLION)
TABLE 240. VIETNAM RESPIRATORY DISEASE TESTING MARKET SIZE, BY INFECTIOUS RESPIRATORY DISEASES, 2018-2030 (USD MILLION)
TABLE 241. VIETNAM RESPIRATORY DISEASE TESTING MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
TABLE 242. EUROPE, MIDDLE EAST & AFRICA RESPIRATORY DISEASE TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 243. EUROPE, MIDDLE EAST & AFRICA RESPIRATORY DISEASE TESTING MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
TABLE 244. EUROPE, MIDDLE EAST & AFRICA RESPIRATORY DISEASE TESTING MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
TABLE 245. EUROPE, MIDDLE EAST & AFRICA RESPIRATORY DISEASE TESTING MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 246. EUROPE, MIDDLE EAST & AFRICA RESPIRATORY DISEASE TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 247. EUROPE, MIDDLE EAST & AFRICA RESPIRATORY DISEASE TESTING MARKET SIZE, BY TEST PURPOSE, 2018-2030 (USD MILLION)
TABLE 248. EUROPE, MIDDLE EAST & AFRICA RESPIRATORY DISEASE TESTING MARKET SIZE, BY DISEASES TYPE, 2018-2030 (USD MILLION)
TABLE 249. EUROPE, MIDDLE EAST & AFRICA RESPIRATORY DISEASE TESTING MARKET SIZE, BY CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD), 2018-2030 (USD MILLION)
TABLE 250. EUROPE, MIDDLE EAST & AFRICA RESPIRATORY DISEASE TESTING MARKET SIZE, BY INFECTIOUS RESPIRATORY DISEASES, 2018-2030 (USD MILLION)
TABLE 251. EUROPE, MIDDLE EAST & AFRICA RESPIRATORY DISEASE TESTING MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
TABLE 252. EUROPE, MIDDLE EAST & AFRICA RESPIRATORY DISEASE TESTING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 253. DENMARK RESPIRATORY DISEASE TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 254. DENMARK RESPIRATORY DISEASE TESTING MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
TABLE 255. DENMARK RESPIRATORY DISEASE TESTING MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
TABLE 256. DENMARK RESPIRATORY DISEASE TESTING MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 257. DENMARK RESPIRATORY DISEASE TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 258. DENMARK RESPIRATORY DISEASE TESTING MARKET SIZE, BY TEST PURPOSE, 2018-2030 (USD MILLION)
TABLE 259. DENMARK RESPIRATORY DISEASE TESTING MARKET SIZE, BY DISEASES TYPE, 2018-2030 (USD MILLION)
TABLE 260. DENMARK RESPIRATORY DISEASE TESTING MARKET SIZE, BY CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD), 2018-2030 (USD MILLION)
TABLE 261. DENMARK RESPIRATORY DISEASE TESTING MARKET SIZE, BY INFECTIOUS RESPIRATORY DISEASES, 2018-2030 (USD MILLION)
TABLE 262. DENMARK RESPIRATORY DISEASE TESTING MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
TABLE 263. EGYPT RESPIRATORY DISEASE TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 264. EGYPT RESPIRATORY DISEASE TESTING MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
TABLE 265. EGYPT RESPIRATORY DISEASE TESTING MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
TABLE 266. EGYPT RESPIRATORY DISEASE TESTING MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 267. EGYPT RESPIRATORY DISEASE TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 268. EGYPT RESPIRATORY DISEASE TESTING MARKET SIZE, BY TEST PURPOSE, 2018-2030 (USD MILLION)
TABLE 269. EGYPT RESPIRATORY DISEASE TESTING MARKET SIZE, BY DISEASES TYPE, 2018-2030 (USD MILLION)
TABLE 270. EGYPT RESPIRATORY DISEASE TESTING MARKET SIZE, BY CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD), 2018-2030 (USD MILLION)
TABLE 271. EGYPT RESPIRATORY DISEASE TESTING MARKET SIZE, BY INFECTIOUS RESPIRATORY DISEASES, 2018-2030 (USD MILLION)
TABLE 272. EGYPT RESPIRATORY DISEASE TESTING MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
TABLE 273. FINLAND RESPIRATORY DISEASE TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 274. FINLAND RESPIRATORY DISEASE TESTING MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
TABLE 275. FINLAND RESPIRATORY DISEASE TESTING MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
TABLE 276. FINLAND RESPIRATORY DISEASE TESTING MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 277. FINLAND RESPIRATORY DISEASE TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 278. FINLAND RESPIRATORY DISEASE TESTING MARKET SIZE, BY TEST PURPOSE, 2018-2030 (USD MILLION)
TABLE 279. FINLAND RESPIRATORY DISEASE TESTING MARKET SIZE, BY DISEASES TYPE, 2018-2030 (USD MILLION)
TABLE 280. FINLAND RESPIRATORY DISEASE TESTING MARKET SIZE, BY CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD), 2018-2030 (USD MILLION)
TABLE 281. FINLAND RESPIRATORY DISEASE TESTING MARKET SIZE, BY INFECTIOUS RESPIRATORY DISEASES, 2018-2030 (USD MILLION)
TABLE 282. FINLAND RESPIRATORY DISEASE TESTING MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
TABLE 283. FRANCE RESPIRATORY DISEASE TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 284. FRANCE RESPIRATORY DISEASE TESTING MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
TABLE 285. FRANCE RESPIRATORY DISEASE TESTING MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
TABLE 286. FRANCE RESPIRATORY DISEASE TESTING MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 287. FRANCE RESPIRATORY DISEASE TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 288. FRANCE RESPIRATORY DISEASE TESTING MARKET SIZE, BY TEST PURPOSE, 2018-2030 (USD MILLION)
TABLE 289. FRANCE RESPIRATORY DISEASE TESTING MARKET SIZE, BY DISEASES TYPE, 2018-2030 (USD MILLION)
TABLE 290. FRANCE RESPIRATORY DISEASE TESTING MARKET SIZE, BY CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD), 2018-2030 (USD MILLION)
TABLE 291. FRANCE RESPIRATORY DISEASE TESTING MARKET SIZE, BY INFECTIOUS RESPIRATORY DISEASES, 2018-2030 (USD MILLION)
TABLE 292. FRANCE RESPIRATORY DISEASE TESTING MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
TABLE 293. GERMANY RESPIRATORY DISEASE TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 294. GERMANY RESPIRATORY DISEASE TESTING MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
TABLE 295. GERMANY RESPIRATORY DISEASE TESTING MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
TABLE 296. GERMANY RESPIRATORY DISEASE TESTING MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 297. GERMANY RESPIRATORY DISEASE TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 298. GERMANY RESPIRATORY DISEASE TESTING MARKET SIZE, BY TEST PURPOSE, 2018-2030 (USD MILLION)
TABLE 299. GERMANY RESPIRATORY DISEASE TESTING MARKET SIZE, BY DISEASES TYPE, 2018-2030 (USD MILLION)
TABLE 300. GERMANY RESPIRATORY DISEASE TESTING MARKET SIZE, BY CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD), 2018-2030 (USD MILLION)
TABLE 301. GERMANY RESPIRATORY DISEASE TESTING MARKET SIZE, BY INFECTIOUS RESPIRATORY DISEASES, 2018-2030 (USD MILLION)
TABLE 302. GERMANY RESPIRATORY DISEASE TESTING MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
TABLE 303. ISRAEL RESPIRATORY DISEASE TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 304. ISRAEL RESPIRATORY DISEASE TESTING MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
TABLE 305. ISRAEL RESPIRATORY DISEASE TESTING MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
TABLE 306. ISRAEL RESPIRATORY DISEASE TESTING MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 307. ISRAEL RESPIRATORY DISEASE TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 308. ISRAEL RESPIRATORY DISEASE TESTING MARKET SIZE, BY TEST PURPOSE, 2018-2030 (USD MILLION)
TABLE 309. ISRAEL RESPIRATORY DISEASE TESTING MARKET SIZE, BY DISEASES TYPE, 2018-2030 (USD MILLION)
TABLE 310. ISRAEL RESPIRATORY D

Companies Mentioned

  • Abbott Laboratories
  • AstraZeneca PLC
  • Becton, Dickinson and Company
  • Bio-Rad Laboratories, Inc.
  • Biomérieux PLC
  • Charles River Laboratories
  • COSMED srl
  • Eurofins Viracor, LLC
  • F. Hoffmann-La Roche Ltd.
  • Fujifilm Holdings
  • GE Healthcare
  • Koninklijke Philips N.V
  • Medtronic PLC
  • MGC Diagnostics Corporation by Caire Inc.
  • QIAGEN Group
  • ResMed
  • SDI Diagnostics, Inc.
  • Seegene Inc.
  • Seimens Healthineers AG
  • Thermo Fisher Scientific

Methodology

Loading
LOADING...

Table Information

Report AttributeDetails
No. of Pages197
PublishedMarch 2025
Forecast Period2025 - 2030
Estimated Market Value ( USD ) in 2025 $ 6.86 Billion
Forecasted Market Value ( USD ) by 2030 $ 9.18 Billion
Compound Annual Growth Rate5.9%
Regions CoveredGlobal
No. of Companies Mentioned20

Related Topics

Related Reports

Respiratory Disease Testing - Market Insights, Competitive Landscape, and Market Forecast - 2030 - Product Image

Respiratory Disease Testing - Market Insights, Competitive Landscape, and Market Forecast - 2030

  • Report
  • 150 Pages
  • Global
From
Respiratory Disease Testing Market Report 2025 - Product Image

Respiratory Disease Testing Market Report 2025

  • Report
  • 200 Pages
  • Global
From
Respiratory Disease Testing Market Analysis & Forecast to 2024-2034 - Product Image

Respiratory Disease Testing Market Analysis & Forecast to 2024-2034

  • Report
  • 200 Pages
  • Global
From
Respiratory Disease Testing - Global Strategic Business Report - Product Image

Respiratory Disease Testing - Global Strategic Business Report

  • Report
  • 158 Pages
  • Global
From
2024 Global Respiratory Disease Testing Market: Unmet Needs, Supplier Shares and Strategies, Segment Volume and Sales Forecasts for Major Assays, Emerging Technologies and Trends, Instrumentation Pipeline, Growth Opportunities for Suppliers - Product Image

2024 Global Respiratory Disease Testing Market: Unmet Needs, Supplier Shares and Strategies, Segment Volume and Sales Forecasts for Major Assays, Emerging Technologies and Trends, Instrumentation Pipeline, Growth Opportunities for Suppliers

  • Report
  • Global
From

About the Respiratory Disease Test Market

The Respiratory Disease Test market within the context of Diagnostics is a rapidly growing sector, as respiratory diseases are among the most common illnesses worldwide. Tests for respiratory diseases are used to diagnose and monitor a variety of conditions, including asthma, chronic obstructive pulmonary disease (COPD), and pneumonia. These tests can be conducted in a variety of ways, including imaging tests, pulmonary function tests, and laboratory tests. Imaging tests such as X-rays and CT scans are used to detect abnormalities in the lungs, while pulmonary function tests measure the amount of air a person can inhale and exhale. Laboratory tests, such as sputum tests, are used to detect the presence of bacteria or viruses in the lungs. Some companies in the Respiratory Disease Test market include Abbott Laboratories, Becton Dickinson, Siemens Healthineers, Roche Diagnostics, and Thermo Fisher Scientific. Show Less Read more

Copyright © 2002-2025 Research and Markets. All Rights Reserved.